Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
An account already exists for this email address, please log in.
Are these FTSE 100 pharmaceutical stocks worth a look?
Pharmaceutical stocks are some of the biggest in the FTSE 100. The sector is threatened by tariffs, but some have posted encouraging results regardless.
UK pharmaceuticals are delivering positive results despite potential headwinds. The sector could be worth a look.
Pharmaceutical companies account for some of the top stocks in the FTSE 100, the UK’s flagship index. Astrazeneca (LON:AZN), for example, is the largest stock in the index by market capitalisation at time of writing, ahead of banking giant HSBC and oil major Shell.
There are lots of headwinds driving the space at present. Weight loss drugs offer a potentially huge market for companies like Astrazeneca.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up for MoneyWeek’s free twice-daily newsletter.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
How are the FTSE 100’s biggest pharmaceutical stocks holding up against these pressures? And is now the right time to buy FTSE 100 pharmaceutical stocks?
Astrazeneca
Astrazeneca’s stock has gained 9.6% so far this year, as of 30 July.
On 29 July, Astrazeneca posted a first half revenue increase of 11% to $28 billion, versus the $27.7 billion analysts had expected.
Core earnings per share (EPS) rose 17% to $4.66.
“Meanwhile, the pipeline progress adds confidence that the 2030 revenue target of $80bn is one to meet or beat,” said Derren Nathan, head of equity research at Hargreaves Lansdown.
“Astra’s keeping up a frenetic pace of innovation and commercialisation with 12 positive late stage read outs from clinical trials and 19 approvals in major territories.”
However, Nathan noted disappointment that Astrazeneca did not upgrade its forecast for the year given the strong financials.
He also noted that tariffs are weighing on Astrazeneca’s share price. “These concerns look to have been overplayed with the threat of enormous import levies subsiding for now, and Astra’s $50 billion pledge for US investment likely to leave it in the Trump administration’s good books,” he said.
Astrazeneca’s share price gained 3.4% on 29 July, following the results.
GSK
Shares in GSK (LON:GSK) are up 7.8% so far this year, and the stock gained a boost on 30 July when it posted a strong set of second quarter results.
EPS rose 15% to 46.5p, beating analyst expectations of 41.9p, with revenue increasing 6% to £8 billion. Analysts had forecast revenue slightly below this, at £7.8 billion.
Sales of speciality medicines rose 15%. Within this, the key HIV franchise and oncology (cancer) division grew by 12% and 42% respectively.
“The prognosis for GSK is looking positive,” said Nathan. “It hasn’t let itself get too distracted by tariff uncertainty, with both second-quarter sales and earnings coming in ahead of market forecasts.”
Nathan also noted that current guidance includes the tariffs that have so far been imposed.
GSK stock had gained 3.9% as of 3.45pm following the results.
Haleon
Haleon’s (LON:HLN) stock has fallen 4.8% in the year to date, trailing its larger FTSE 100 companions Astrazeneca and GSK.
Q2 revenue came in at £2.63 billion, below the £2.68 billion analysts had forecast and representing 3.0% in organic revenue growth. That translated into 9.2p per share in adjusted earnings for the first half of 2025.
Haleon’s stock opened 3.1% lower on 31 July following the results.
FTSE 100 pharmaceutical stocks compared
Here’s how these three pharmaceutical stocks are currently priced compared to their past and expected earnings. All data is as of market close on 30 July (before Haleon’s results).
Swipe to scroll horizontally
Header Cell - Column 0
Trailing P/E ratio
Forward P/E ratio
AZN
28.07
16.58
GSK
18.36
8.51
HLN
23.39
19.84
Source: Yahoo Finance
Sign up for MoneyWeek's newsletters
Join more than 165,000 subscribers and keep yourself informed with the latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.
Dan is a financial journalist who, prior to joining MoneyWeek, spent five years writing for OPTO, an investment magazine focused on growth and technology stocks, ETFs and thematic investing.
Before becoming a writer, Dan spent six years working in talent acquisition in the tech sector, including for credit scoring start-up ClearScore where he first developed an interest in personal finance.
Dan studied Social Anthropology and Management at Sidney Sussex College and the Judge Business School, Cambridge University. Outside finance, he also enjoys travel writing, and has edited two published travel books.
